RxDoctor Payments Data

Vanessa Freeman, MD

Psychiatry · Knoxville, TNNPI 1518329267

Payments from drug & device makers

$680in general payments, 2019–2025

Across 21 payments — averaging $32.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$305
  • Neurocrine Biosciences, Inc.$172
  • Sunovion Pharmaceuticals Inc.$73
  • Teva Pharmaceuticals USA, Inc.$40
  • Lundbeck LLC$32
  • Takeda Pharmaceuticals U.S.A., Inc.$23
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$680 in reported general payments places this provider in the 60th percentile of 503 psychiatry providers in Tennessee.

See all psychiatry providers in Tennessee

Medicare billing

Part B allowed, 2024
$32,629
Medicare patients
25
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl43$59,863
Trazodone Hcl49$1,942
Bupropion XlBupropion Hcl66$1,682
Clozapine12$1,654
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$1,260
Aripiprazole74$1,072
Gabapentin83$1,049
Duloxetine Hcl39$980
Oxcarbazepine17$884
Divalproex Sodium ErDivalproex Sodium26$817
Clonazepam140$793
Lamotrigine79$742
Lithium Carbonate ErLithium Carbonate27$650
Buspirone Hcl28$607
Memantine Hcl33$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$305$59,86343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 503 psychiatry providers in Tennessee.

Other psychiatry in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →